BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 29305295)

  • 1. The Hippo pathway in normal development and cancer.
    Maugeri-Saccà M; De Maria R
    Pharmacol Ther; 2018 Jun; 186():60-72. PubMed ID: 29305295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
    Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
    EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research advances in the role of the Hippo-YAP/TAZ signaling pathway in primary liver cancer].
    Guo LW; Shao GL
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):878-880. PubMed ID: 29325286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP/TAZ at the Roots of Cancer.
    Zanconato F; Cordenonsi M; Piccolo S
    Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hippo Pathway in Prostate Cancer.
    Salem O; Hansen CG
    Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
    Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
    J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
    Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
    Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
    Budel SJ; Penning MM; Penning LC
    Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M; Kim T; Johnson RL; Lim DS
    Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
    Kim MH; Kim J
    Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.
    Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL
    Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic control of YAP and TAZ by the mevalonate pathway.
    Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
    Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.